Trial NCT05043259
Publication Li JX, Lancet Respir Med, 2022
Primary outcome on the report: 1) Incidence of adverse reactions within 14 days after the booster dose; 2) Geometric mean titres (GMTs) of neutralising antibodies against live SARS-CoV-2 virus at 14 days after the booster dose

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.